Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.67 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28869329 | 0.94 | MAPT (1.00) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL20236897 | 0.88 | MAPT (0.88) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL3949148 | 0.88 | MAPT (0.88) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL4559572 | 0.87 | SMN1; SMN2 (0.91) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL8361624 | 0.87 | SMN1; SMN2 (0.97) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL5195426 | 0.86 | SMN1; SMN2 (1.00) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL1575142 | 0.85 | MAPT (0.63) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL13234920 | 0.85 | MAPT (0.87) | MAPTSMN1; SMN2BLMKMT2AHTR1A | |
| SCHEMBL22217877 | 0.85 | MAPT (0.77) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 | |
| SCHEMBL20236190 | 0.84 | MAPT (0.80) | MAPTSMN1; SMN2BLMKMT2ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331864-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| CN-108137518-B | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-08-31 | — | — | CN | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| EP-3331864-A2 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-13 | — | — | EP | disclosed |
| US-20120238563-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | CID-NUNEZ JOSE MARIA (ES) | 2012-09-20 | — | — | US | disclosed |
| US-20120238563-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | CID-NUNEZ JOSE MARIA (ES) | 2012-09-20 | — | — | US | disclosed |
| US-20120035170-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | NUNEZ JOSE MARIA (ES) | 2012-02-09 | — | — | US | disclosed |
| US-20120035170-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | NUNEZ JOSE MARIA (ES) | 2012-02-09 | — | — | US | disclosed |
| US-8022102-B2 | Unsaturated tetracyclic tetrahydrofuran derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022102-B2 | Unsaturated tetracyclic tetrahydrofuran derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035170-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | HTR2C, HTR2A, HTR1A | MAPT 2632/4885SMN1; SMN2 883/4885BLM 4879/4885 |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | MAPT 1165/4885SMN1; SMN2 3974/4885BLM 1508/4885 |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | HTR2C, HTR2A, HTR1A | MAPT 2296/4885SMN1; SMN2 979/4885BLM 4874/4885 |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | MAPT 3204/4885SMN1; SMN2 4060/4885BLM 2096/4885 |
| US-20120238563-A1 | NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | HTR2C, HTR2A, HTR1A | MAPT 2632/4885SMN1; SMN2 883/4885BLM 4879/4885 |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC5, HDAC2 | MAPT 1679/4885SMN1; SMN2 752/4885BLM 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.